Chinese Trial: Stem Cell Injections Restored Heart Function in 9 of 10 Failure Patients

Doctors in China say they got 9 out of 10 severe heart failure patients breathing easier, walking farther, and pumping more blood after injecting them with lab-grown heart muscle cells during bypass surgery. The results came from a 20-patient trial and were published in the journal Nature Medicine, according to the South China Morning Post.

The therapy, called HiCM-188, comes from HELP Therapeutics, a biopharmaceutical company based in Nanjing. The company put out its own announcement through TradingView on August 20, 2026, describing 12-month results from what it calls the HEAL-CHF trial.

Researchers took the patients' own cells and reprogrammed them into induced pluripotent stem cells, or iPSCs, which can turn into almost any cell type in the body. They then coaxed those iPSCs into becoming heart muscle cells and injected them directly into damaged heart tissue during coronary artery bypass grafting surgery, according to The Independent.

Ten patients got the bypass surgery plus the cell injections. Ten patients got bypass surgery alone as the control group. At the 12-month mark, 90% of the treated patients had improved to New York Heart Association Class II, meaning mild symptoms during normal activity. Only 60% of the bypass-only group reached that level, according to HELP Therapeutics' own release.

The treated group also did almost twice as well on a six-minute walking test compared to the control group, The Independent reported. One patient in the control group died eight months after surgery. No deaths were reported in the treatment group.

Safety numbers matter here too

HELP Therapeutics said the trial hit its safety targets: no treatment-related tumors through 12 months and no sustained dangerous arrhythmia through six months. The Independent noted two patients did develop clinically significant tachycardia, a fast heart rhythm, but it resolved on its own two to three weeks after the procedure.

Professor Dongjin Wang, director of cardiothoracic surgery at Nanjing Drum Tower Hospital and the study's lead author, called it "the first clinical evidence that delivering HiCM-188 intraoperatively during CABG may combine the benefits of revascularization with myocardial regeneration."

Dr. Eugene Jiaxian Wang, CEO of HELP Therapeutics, said the company now has a Phase III trial enrolling patients in China through TEDA International Cardiovascular Hospital, plus a Phase I trial underway in the United States at the Texas Heart Institute. HiCM-188 is reportedly the first iPSC-derived heart cell therapy to get investigational drug clearance from both the U.S. FDA and China's National Medical Products Administration.

Why this isn't a cure yet

Twenty patients is not a lot of people. This is a Phase 2 study, one step in a process that normally requires a much larger Phase 3 trial before any regulator approves a therapy for widespread use. The researchers themselves said future studies are needed to nail down the "risk-to-benefit ratio," according to The Independent.

Heart transplants remain the only actual cure for end-stage heart failure right now, and donor hearts are scarce. If this therapy holds up in larger trials, it could give doctors another option for patients who will never get a transplant.

But dead heart muscle still can't regrow on its own, and this technology is being framed as helping aging or damaged hearts grow new tissue, not resurrecting cells that are already gone, according to the South China Morning Post.

A separate point worth flagging

None of this trial data has anything to do with Chinese Communist Party propaganda, and readers shouldn't confuse the two. Separately, the Epoch Times published a critique of a China Daily opinion piece by Robert Lawrence Kuhn that credited the CCP's one-party system for China's economic growth since 1978. The Epoch Times, a right-leaning outlet with a long history of covering the CCP critically, argued that growth actually took off when Deng Xiaoping's government loosened Maoist economic controls, not because centralized Party rule caused prosperity.

That argument is a legitimate point about how to interpret Chinese economic history, and it deserves its own space. It has zero bearing on whether a Nanjing hospital's heart therapy trial produced real, peer-reviewed results. Nature Medicine is an internationally respected, independently peer-reviewed journal, not a state propaganda outlet, and publication there means outside scientists reviewed the trial's methods and data before it ran.

The open question now is straightforward: will HiCM-188 hold up when hundreds of patients are enrolled in the Phase III trial rather than just 20? That data, plus whatever comes out of the Texas Heart Institute's Phase I work, will determine whether this becomes a real treatment option or joins the long list of promising small trials that didn't scale.